BIOGEN Inc. and Elan corporation PLC.(Companies to cooperate to develop monoclonal antibodies for treatment of MS and Crohn's disease)(Brief Article)

Chemical Market Reporter, August, 2000

BIOGEN Inc. and Elan corporation PLC have formed an agreement to develop, manufacture and commercialize Antegren (natalizumab), a humanized monoclonal antibody nearing completion of Phase II clinical trails for treating multiple sclerosis and Crohn's disease.

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement
Click Here